Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Supernus Pharmaceuticals Inc. : Supernus Appoints Victor Vaughn as Senior Vice President of Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/15/2013 | 01:52am CET

ROCKVILLE, Md., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the appointment of Victor Vaughn to the position of Senior Vice President of Sales. Mr. Vaughn will be responsible for leading all of the company's sales activities.

"Victor has an outstanding track record of success in building sales organizations and launching specialty products specifically in the epilepsy and ADHD areas. He led the Shire sales organization for 13 years with sales reaching more than $1 billion behind products including Carbatrol® in epilepsy and Adderall XR® in ADHD," said Jack Khattar, president and CEO of Supernus. "Victor has been working with us for more than three years in a consulting capacity helping to build our sales organization and to prepare for the launches of Oxtellar XR™ and Trokendi XR™. We are very excited to have him join us on a full time basis as a member of our executive team. Victor's significant experience in executing one of the most successful immediate release (IR) to extended release (XR) switches in our industry will be pivotal to our execution on the upcoming launches of our two epilepsy XR products."

Mr. Vaughn has over 30 years of experience in the pharmaceutical industry. For the past seven years he has been consulting with small to medium size pharmaceutical companies, assisting them with their commercial operations. From 1992 to 2005, he led the sales organization at Shire where he last served as senior vice president of sales. Prior to that, he held various positions in sales and sales management at Fujisawa and SmithKline Beecham (Glaxo). Mr. Vaughn earned his bachelor degree in business administration from East Tennessee State University.

"I am excited to be joining the Supernus team and working on launching two important products in epilepsy," said Victor Vaughn, senior vice president of sales. " I am very much looking forward to being part of the great growth opportunity that lies ahead for Supernus and to the chance to positively affect the lives of patients suffering from epilepsy, ADHD and other CNS disorders."

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one approved product for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one tentatively approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to raise sufficient capital to implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's products and product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its products and product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's staffing needs; and other risk factors set forth from time to time in the Company's periodic reports and other filings made with the Securities and Exchange Commission. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

Carbatrol® and Adderall XR® are registered trademarks of Shire LLC

CONTACT: Jack Khattar, President & CEO

         Gregory S. Patrick, Vice President and CFO

         Supernus Pharmaceuticals, Inc.

         Tel: (301) 838-2591
Source: Supernus Pharmaceuticals, Inc.

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
08:59p GOVERNMENT OF FINLAND : Prime Minister Sipilä after the inauguration of the new President of the United States
08:59p NASEO NATIONAL ASSOCIATION OF STATE ENERGY OFFIC : President Trump Issues Statement on Energy Priorities
08:59p DOMINION RESOURCES : U.S. signs off on third reactor at North Anna
08:59pDJSCHLUMBERGER : U.S. Oil Producers Ramp Up Spending--Update
08:54p NOVUS ROBOTICS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
08:54p CANADIAN FUELS ASSOCIATION : Plenty of life left in the internal combustion engine
08:53p WARREN BUFFETT : AIG to pay Buffett's Berkshire about $10 billion in insurance deal
08:53p JACLYN, INC. : Agrees to Be Acquired by an Affiliate of Golden Touch Imports, Inc. for $7.85 per Share
08:51p A.M. BESTTV : Heads of U.S. Industry Associations Face Off on Covered Agreement Deal
08:51p NORDSTROM : Loyalty Program Expands to Include Trunk Club Purchases
Latest news
Advertisement
Hot News 
-2.72%GENERAL ELECTRIC : Nason, former Treasury official, being vetted for Fed role - sources
12.40%SYNTHOMER : Chemicals maker Synthomer sees 2016 profit ahead of estimates
-6.24%European shares ease ahead of Trump inauguration
1.85%Rockwell Collins Confident on Jet Ramp -- 2nd Update
1.84%IBM revenue fall dims upbeat profit forecast
Most Read News
09:33a BLACKROCK : Fears of economic 'race to bottom', strong dollar in Davos
02:05p GENERAL ELECTRIC : GE looks for sharp cut in corporate tax rate under Trump
11:11a TSX Jumps one percent as oil rally boosts energy stocks; Trump eyed
12:16aDJNEWS HIGHLIGHTS : Top Energy News of the Day
01/19 TESLA MOTORS : U.S. regulator finds no evidence of defects after Tesla death probe
Most recommended articles
01/17DJS&P 500, Nasdaq Futures -- Technical Analysis
02:53p WARREN BUFFETT : AIG to pay Buffett's Berkshire about $10 billion in insurance deal
02:40p Toshiba making preparations for sale of stake in chip business -sources
02:24p ALPHABET : Uber hires Google search veteran Singhal for senior engineering post
02:23p FTC NOT SOLD ON WALGREENS' PLAN TO WIN NOD FOR RITE AID DEAL : Bloomberg